China "demonized" on fake drugs, says SFDA

26 May 2009

Reports from China offer evidence of the inconsistency of public authorities when dealing with fake or substandard drugs. Xinhua, the  government news agency, reported that Xiong Xuanguo, the Vice President  of the Supreme People's Court, had stated that the issue has become a  cause of discontent. He said that fake or poorly-manufactured  medicines "seriously harm people's health, disturb the healthy  development of the pharmaceutical industry in China and severely damage  the image of the country internationally." Mr Xiong announced a new  interpretation of the country's legal code to allow stiffer punishments.

However, Bian Zhenjia, Deputy Director of the State Food and Drug  Administration complained at a news conference that "foreign media" was  fabricating stories and foreign drugmakers were ignoring regulations,  Reuters reported.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight